<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428050</url>
  </required_header>
  <id_info>
    <org_study_id>Jefferson Hypertonic</org_study_id>
    <nct_id>NCT01428050</nct_id>
  </id_info>
  <brief_title>The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Prospective Randomized Controlled Trial on the Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Whipple operation is a complex surgical procedure involving the removal of the head of
      the pancreas, bile duct, and a portion of the intestine (duodenum) that is performed for
      patients who have cancer or some other condition affecting this region of the body. The
      Whipple operation is associated with a significant complication rate. Previous studies have
      shown that in a broad range of surgical procedures, using a reduced amount of intravenous
      fluids along with a special type of fluid called hypertonic saline during and after the
      procedure can lower complication rates associated with the heart and lungs during recovery
      from surgery. The purpose of this study is to determine if using a reduced amount of
      intravenous fluids as well as hypertonic saline (a salt concentrated form of intravenous
      fluids) during the Whipple operation and in the immediate period after surgery can reduce
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anastomotic Leak</measure>
    <time_frame>30 days</time_frame>
    <description>Leak or defect of gastrointestinal anastomosis including but not limited to pancreaticojejunostomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delayed Gastric Emptying</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of delayed gastric emptying post procedure, prolonged initiation of enteral feeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Infection</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>3% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15cc/kg/hr of lactated ringers solution intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% NaCl Solution</intervention_name>
    <description>1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution</description>
    <arm_group_label>3% saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactated Ringers Solution</intervention_name>
    <description>15cc/kg/hr for intraoperative fluids</description>
    <arm_group_label>Lactated Ringers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physiologic suitability for major abdominal surgery

          -  Aged 18 years and older

          -  Written informed consent

          -  Ability to understand and comply with study guidelines

          -  Ability to obtain a central venous line

        Exclusion Criteria:

          -  Metabolic acidosis

          -  Active Sepsis or Bacteremia

          -  Chronic renal insufficiency

          -  Hyponatremia (serum sodium &lt;130)

          -  Hypernatremia (serum sodium &gt;150)

          -  Pregnancy

          -  Sickle cell anemia

          -  Pediatric patients

          -  BMI&gt;40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harish Lavu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harish Lavu, MD</last_name>
    <phone>215-955-9402</phone>
    <email>harish.lavu@jeffersonhospital.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harish Lavu, MD</last_name>
      <phone>215-955-9402</phone>
      <email>Harish.Lavu@jeffersonhospital.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>whipple</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>fluid restriction</keyword>
  <keyword>resuscitation strategy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

